Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-Exo S1
- Development stage
- Unknown
- Lead developer
- Guangzhou National Laboratory
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
MSC-Exo S1 is a specific subpopulation of mesenchymal stem cell-derived exosomes (MSC-Exo) developed by researchers at the Guangzhou Institute of Respiratory Health, Guangzhou National Laboratory, and The First Affiliated Hospital of Guangzhou Medical University. Administered via nebulized inhalation, MSC-Exo S1 is designed to deliver dual anti-fibrotic and immunomodulatory therapeutic effects directly to the lungs. In preclinical models of pulmonary fibrosis, it has demonstrated the ability to inhibit myofibroblast activation and reduce inflammatory biomarkers. In a first-in-human clinical trial, nebulized MSC-Exo S1 therapy combined with standard of care significantly improved the 3-month survival rate and pulmonary function of patients with anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease (MDA5+DM-RP-ILD).
- Other names
- Mesenchymal Stem Cell-Derived Exosome Subgroup S1Mesenchymal Stem Cell-Derived Exosome Subpopulation S1
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)HIF1A (Hypoxia-inducible factor 1-alpha)IFNG (Interferon gamma)IL10 (Interleukin-10)IL-17A (Interleukin-17A)IL1B (Interleukin-1 beta)IL-2 (Interleukin 2)IL21 (Interleukin-21)IL22 (Interleukin 22)IL-6 (Interleukin 6)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on MSC-Exo S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-Exo S1.